©Reuters.
Turin, Italy – Solidsoft Reply, part of the Reply Group, has completed a major transition from Finland’s National Medicines Verification System to its own National Blueprint solution, setting a precedent within the European Medicines Verification System (EMVS). The project involved the transfer of his over 500 million medicine pack records accumulated over four years and was achieved through a 10-month collaboration with the Finnish Medicines Verification Organization (FiMVO).
The National Blueprint solution developed by Solidsoft Reply leverages Microsoft (NASDAQ:) Azure cloud technology to ensure compliance with the EU False Medicines Directive (FMD). The directive requires the certification of medicinal products to prevent counterfeit products from entering the supply chain. This migration is the first of its kind within EMVS and represents a milestone in the medical and pharmaceutical sectors where data integrity and security are critical.
David Eccles, partner at Solidsoft Reply, emphasized that this transition is a testament to engineering expertise and a collaborative approach. The success of the project is due to his partnership with FiMVO, which facilitated overcoming technical challenges and established new standards for the EMVS ecosystem.
FiMVO General Manager Maija Gohlke praised the professionalism of the Solidsoft Reply team, saying their knowledge, dedication and flexibility exceeded expectations. Particular praise was given to the smooth execution of the project, despite the complexity and numerous connections within the supply chain.
Solidsoft Reply is recognized as a leading partner for verification and traceability systems around the world, especially in the pharmaceutical and healthcare industries. Finland’s successful system transition demonstrates the company’s commitment to strengthening health systems through advanced technology and contributing to the safety and effectiveness of health care delivery.
This news is based on a statement in a press release.
This article was generated with the help of AI and reviewed by an editor. Please see our Terms of Use for more information.